Inclisiran—will it fulfill its promise?
Nutrition, Metabolism and Cardiovascular Diseases · 2026
DOI: 10.1016/j.numecd.2026.104848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026. Verfasst von Seyed Saeed Tamehri Zadeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences, Tehran, …. Hauptthemen laut MEDLINE: Cholesterol, LDL, Atherosclerosis, Hyperlipoproteinemia Type II, PCSK9 Inhibitors. Die Arbeit nennt 116 Literaturangaben.
Abstract (Originalsprache)
AIMS: Elevated low-density lipoprotein cholesterol (LDL-C) is a well-established, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), with absolute LDL-C reduction translating into proportional reductions in ASCVD events. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an effective lipid-lowering strategy. This review summarizes current evidence on the efficacy and safety of inclisiran, a small interfering RNA (siRNA) therapy that inhibits hepatic PCSK9 synthesis, in primary and secondary ASCVD prevention, as well as in heterozygous familial hypercholesterolaemia (HeFH) and homozygous familial hypercholesterolaemia (HoFH). DATA SYNTHESIS: Randomized clinical trials have demonstrated that inclisiran produces robust and sustained reductions in LDL-C and circulating PCSK9 levels across a broad spectrum of patients, including those with established ASCVD, ASCVD risk equivalents, and FH. Its twice-yearly dosing regimen may substantially improve long-term treatment adherence. Long-term data (up to 6 years) indicate a favorable safety and tolerability profile, with no dose adjustments required in patients with renal or hepatic impairment. Ongoing randomized outcome trials are expected to clarify the impact of inclisiran on ASCVD events. CONCLUSION: Current evidence supports its role as a promising adjunct or alternative to established lipid-lowering therapies, including statins, particularly in patients requiring additional LDL-C reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: tamehrysaeed@gmail.com.
- Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum-University of Bologna, Sant' Orsola-Malpighi Hospital, Bologna, 40138, Italy.
- Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Tamehri Zadeh, S. S., Fogacci, F., & Hadaegh, F. (2026). Inclisiran—will it fulfill its promise?. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2026.104848
Vancouver
Tamehri Zadeh SS, Fogacci F, Hadaegh F. Inclisiran—will it fulfill its promise?. Nutrition, Metabolism and Cardiovascular Diseases. 2026. doi:10.1016/j.numecd.2026.104848
BibTeX
@article{TamehriZadeh2026,
author = {Tamehri Zadeh, Seyed Saeed and Fogacci, Federica and Hadaegh, Farzad},
title = {Inclisiran—will it fulfill its promise?},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.numecd.2026.104848}
}
EUVIMED